Information for Patients & Healthcare Professionals:

Thalidomide BMS® (thalidomide) can cause severe birth defects or death to an unborn baby therefore:

- Female patients of childbearing potential must always use effective contraception and male patients with pregnant partners or partners of childbearing potential not using effective contraception must always use condoms (even if the man has had a vasectomy)
- Female patients of childbearing potential must have pregnancy tests every 4 weeks, prior to each prescription, to ensure that they are not pregnant, except in the case of confirmed tubal sterilisation
- If a patient or partner of a patient suspects they are pregnant they must contact their prescriber or doctor immediately.

For complete information on the side effects of Thalidomide BMS®, patients should read the Package Leaflet and Healthcare Professionals should read the Summary of Product Characteristics.

Date of preparation of text: April 2022 Approved by MHRA: November 2022

Information for Healthcare Professionals:

Prescription Details

Has the patient received counselling?:	Yes No
Childbearing potential assessment:	WCBP / WNCBP / Male
If the patient is a WCBP is she using effective contraception?:	Yes No
If the patient is male, is he using condoms, if required?:	Yes No

Information for Healthcare Professionals:

Prescription Details

A completed Prescription Authorisation Form must accompany each prescription to confirm that the patient continues to use effective contraception (if required) and, in the case of a WCBP, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant.

Emergency contact information:

Emergency Prescriber Contact:
Telephone number during office hours:
Telephone number after office hours: